SB
COGT icon

Samsara BioCapital’s Cogent Biosciences COGT Stock Holding History

Samsara BioCapital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-588,961
Closed -$6.61M – 45
2020
Q4 		$6.61M Sell
588,961
-831,494
-59% -$9.14M 0.67% 17
2020
Q3 		$13.3M Buy
+1,420,455
New +$14.8M 3.71% 9

Other funds holding COGT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Samsara BioCapital's COGT Position: Q1 2021 in Review

Samsara BioCapital sold out of Cogent Biosciences (COGT) in Q1 2021, closing a stake of 588,961 shares — an estimated $6.61M sold.

Samsara BioCapital first reported a position in COGT in Q3 2020 and held it in 2 quarters. The position peaked at $13.3M in Q3 2020. 69 funds tracked by Wall St. Rank hold COGT as of Q1 2021.

  • Samsara BioCapital reported no remaining Cogent Biosciences position as of Q1 2021 after selling out during the quarter.
  • Samsara BioCapital sold 588,961 Cogent Biosciences shares in Q1 2021, an estimated $6.61M.
  • Samsara BioCapital first reported a position in Cogent Biosciences in Q3 2020 and held it in 2 quarters.
  • Samsara BioCapital's Cogent Biosciences position peaked at $13.3M in Q3 2020.
  • 69 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2021.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.